, Volume 52, Issue 9, pp 1971-1973

First online:

Open Access This content is freely available online to anyone, anywhere at any time.

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

  • J. RosenstockAffiliated withUniversity of Texas Southwestern Medical SchoolDallas Diabetes and Endocrine Center at Medical City Email author 
  • , V. FonsecaAffiliated withTulane University Medical Center
  • , J. B. McGillAffiliated withWashington University School of Medicine
  • , M. RiddleAffiliated withOregon Health and Science University
  • , J. P. HalléAffiliated withUniversité de Montréal
  • , I. HramiakAffiliated withUniversity of Western Ontario
  • , P. JohnstonAffiliated withsanofi-aventis
  • , M. DavisAffiliated withUniversity of Wisconsin School of Medicine and Public Health


Cancer Insulin analogues Insulin glargine Insulin therapy Malignancy NPH insulin Type 2 diabetes